Latest filing published 06 Jan 2026 for Regeneron Pharmaceuticals, INC.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Michael S. Brown in Regeneron Pharmaceuticals, Inc., where the filings describe the role as board member. The record holds 21 filings, for trades running from 5 November 2015 to 2 January 2026.
No open-market purchase appears, only 3 sales worth €3.3M. The rest of the record consists of 5 share grants and 12 option exercises.
The newest entry dates from 6 January 2026: a share grant, in Regeneron Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
21 of 21 declarations